

BRCC3 antibody - C-terminal region
Rabbit Polyclonal Antibody
Catalog # AI14755**Specification**

BRCC3 antibody - C-terminal region - Product Information

Application	WB
Primary Accession	P46736
Other Accession	NM_024332 , NP_077308
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig
Predicted	Human, Mouse, Rat, Rabbit, Pig, Chicken, Horse, Bovine, Guinea Pig
Host	Rabbit
Clonality	Polyclonal
Calculated MW	35kDa KDa

BRCC3 antibody - C-terminal region - Additional Information**Gene ID** 79184**Alias Symbol** BRCC36, C6.1A, CXorf53, RP11-143H17.2**Other Names**

Lys-63-specific deubiquitinase BRCC36, 3.4.19.-, BRCA1-A complex subunit BRCC36, BRCA1/BRCA2-containing complex subunit 3, BRCA1/BRCA2-containing complex subunit 36, BRISC complex subunit BRCC36, BRCC3, BRCC36, C6.1A, CXorf53

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-BRCC3 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

BRCC3 antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

BRCC3 antibody - C-terminal region - Protein Information**Name** BRCC3**Synonyms** BRCC36, C6.1A, CXorf53**Function**

Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:20656690, PubMed:20656690)

[24075985](http://www.uniprot.org/citations/24075985), PubMed:<[26344097](http://www.uniprot.org/citations/26344097)>). Does not have activity toward 'Lys- 48'-linked polyubiquitin chains (PubMed:<[19214193](http://www.uniprot.org/citations/19214193)>, PubMed:<[20656690](http://www.uniprot.org/citations/20656690)>, PubMed:<[24075985](http://www.uniprot.org/citations/24075985)>, PubMed:<[26344097](http://www.uniprot.org/citations/26344097)>). Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs) (PubMed:<[14636569](http://www.uniprot.org/citations/14636569)>, PubMed:<[19202061](http://www.uniprot.org/citations/19202061)>, PubMed:<[16707425](http://www.uniprot.org/citations/16707425)>, PubMed:<[17525341](http://www.uniprot.org/citations/17525341)>, PubMed:<[19261748](http://www.uniprot.org/citations/19261748)>, PubMed:<[19261749](http://www.uniprot.org/citations/19261749)>, PubMed:<[19261746](http://www.uniprot.org/citations/19261746)>). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:<[20656690](http://www.uniprot.org/citations/20656690)>). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:<[20656690](http://www.uniprot.org/citations/20656690)>, PubMed:<[24075985](http://www.uniprot.org/citations/24075985)>, PubMed:<[26195665](http://www.uniprot.org/citations/26195665)>, PubMed:<[26344097](http://www.uniprot.org/citations/26344097)>). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:<[19214193](http://www.uniprot.org/citations/19214193)>). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:<[26195665](http://www.uniprot.org/citations/26195665)>). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:<[24075985](http://www.uniprot.org/citations/24075985)>, PubMed:<[26344097](http://www.uniprot.org/citations/26344097)>). Acts as a regulator of the NLRP3 inflammasome by mediating deubiquitination of NLRP3, leading to NLRP3 inflammasome assembly (By similarity). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:<[24075985](http://www.uniprot.org/citations/24075985)>). Deubiquitinates HDAC1 and PWWP2B leading to their stabilization (By similarity).

Cellular Location

Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole Note=Localizes at sites of DNA damage at double-strand breaks (DSBs) (PubMed:20656690, PubMed:26344097). Interaction with ABRAXAS2 retains BRCC3 in the cytoplasm (PubMed:20656690).

Tissue Location

Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Aberrantly expressed in the vast majority of breast tumors.


BRCC3 antibody - C-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)

- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

BRCC3 antibody - C-terminal region - Images



WB Suggested Anti-BRCC3 Antibody Titration: 1.0 µg/ml
Positive Control: MDA-MB-435S Whole Cell

BRCC3 antibody - C-terminal region - References

Kenwrick S., et al. Hum. Mol. Genet. 1:179-186(1992).
Fisch P., et al. Oncogene 8:3271-3276(1993).
Dong Y., et al. Mol. Cell 12:1087-1099(2003).
Ota T., et al. Nat. Genet. 36:40-45(2004).
Ross M.T., et al. Nature 434:325-337(2005).